Grading the Twitterverse's 2013 Biotech Stock Picks

BOSTON ( TheStreet) -- Last January, I invited my Twitter followers to make their own biotech stock predictions for 2013. Let's check in to see whose crystal ball was in fine working order.

Amarin ( AMRN) has been a big loser, which makes @Sport234a2b a big winner!

Nope, but Targacept ( TRGT) is up almost 30% this year despite, basically, doing nothing. TRGT Chart TRGT data by YCharts

Cytokinetics ( CYTK) closed Friday at $8.18, so you got that right, even after factoring in the 1-for-6 reverse stock split. No ALS data or partner yet and that heart-failure drug isn't looking so hot.

Fail.

Sarepta Therapeutics ( SRPT) a volatile stock? You betcha. We're still waiting for the actual eteplrisen filing and expected FDA panel, which are now 2014 events.

Amicus Therapeutics ( FOLD) and Incyte ( INCY) are still single.

Martin was kidding, I hope.

I hesitate to congratulate Ben for his prescient prediction because it will only swell his already-robust ego.

A.P. Pharma ( APPA) is not enjoying 2013: APPA Chart APPA data by YCharts

But yes, the "A" drug launches pretty much suck, so good on 'ya!

MannKind ( MNKD) the stock of the year? Not a chance, but shares are up 146% so you get half credit.

Excellent. You were spot on.

Too easy.

Nope. Very little hepatitis C deal-making this year, but Achillion Pharma's ( ACHN) sovaprevir ('1625) remains unpartnered. Correct.

Let's take a look at the year-to-date stock performance of the big-cap biotechs: CELG Chart CELG data by YCharts

Celgene ( CELG)... Booyah! Arena Pharma's ( ARNA) Belviq launch has been a near disaster. Half credit.

O-fer. Better luck next year.

I don't know what Opko Health ( OPK) actually did this year to validate its diagnostics business, but the stock worked. OPK Chart OPK data by YCharts

Congrats. Well done.

Vikram wins best prediction of 2013.

It has been a good year for deal making, maybe not as much as M&A as you predicted however.

The chart says: "Incorrect!" SGMO Chart SGMO data by YCharts

Nice call on Anacor Pharma ( ANAC), but it does illustrate some of the absurd stock moves during this year's biotech bubble. ANAC Chart ANAC data by YCharts

You're right about Aegerion Pharma ( AEGR).

Half right.

Your crystal ball must have run out of batteries.

Sorry... HZNP Chart HZNP data by YCharts

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Biotech Premarket Movers: Cempra, Novavax, Ionis

Biotech Premarket Movers: Cempra, Novavax, Ionis

Amarin (AMRN) Stock Drops After Pricing Public Offering

Amarin (AMRN) Stock Drops After Pricing Public Offering

Tetraphase Executive Profits Hours Before Stock Plummets

Tetraphase Executive Profits Hours Before Stock Plummets

5 Stocks Ready for Breakouts -- Must-See Charts

5 Stocks Ready for Breakouts -- Must-See Charts

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves